免疫相关不良事件与纳武利尤单抗治疗NSCLC疗效的相关性
该研究基于134例晚期或复发NSCLC患者的多机构病历回顾,分析纳武利尤单抗治疗中免疫相关不良事件(irAEs)与疗效的关系。多变量分析显示irAEs与PFS(HR 0.525)和OS(HR 0.282)均呈正相关。
要点
- 134例晚期或复发NSCLC患者中,51%发生irAEs,9%为3-4级,18%需全身皮质类固醇治疗。
- 多变量分析:irAEs与PFS(HR 0.525,95%CI 0.287-0.937)和OS(HR 0.282,95%CI 0.101-0.667)正相关。
核心结论
- 在晚期或复发NSCLC患者中,纳武利尤单抗治疗期间发生irAEs与生存结局相关。
- 需进一步研究确认该发现。
研究设计与样本
- 基于界标分析和多变量分析的研究,共纳入134例晚期或复发NSCLC患者。
- 患者于2015年12月至2016年8月期间在二线或更后线接受纳武利尤单抗治疗,病历来自包括大学医院和社区医院在内的多机构回顾。
- 数据更新至2016年12月31日。
主要发现
- 134例患者中位年龄68岁(范围33-85),男性90例(67%),女性44例(33%)。
- 69例(51%)发生irAEs,其中12例(9%)为3或4级,24例(18%)需全身皮质类固醇治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Immune-related adverse events (irAEs) have been associated with the efficacy of PD-1 (programmed cell death protein 1) inhibitors in patients with melanoma, but whether such an association exists for non-small-cell lung cancer (NSCLC) has remained unknown. OBJECTIVE: To evaluate the relation of irAEs to nivolumab efficacy in NSCLC. DESIGN, SETTING, AND PARTICIPANTS: In this study based on landmark and multivariable analyses, a total of 134 patients with advanced or recurrent NSCLC who were treated with nivolumab in the second-line setting or later between December 2015 and August 2016 were identified from a review of medical records from multiple institutions, including a university hospital and community hospitals. Data were updated as of December 31, 2016. EXPOSURES: The absence or presence of any irAE before the landmark date. MAIN OUTCOMES AND MEASURES: Kaplan-Meier curves of progression-free survival (PFS) according to the development of irAEs in 6-week landmark analysis were evaluated with the log-rank test as a preplanned primary objective. Overall survival (OS) was similarly evaluated. Multivariable analysis of both PFS and OS was performed with Cox proportional hazard regression models. RESULTS: In a cohort of 134 patients (median [range] age, 68 [33-85] years; 90 men [67%], 44 women [33%]), irAEs were observed in 69 of the 134 study patients (51%), including 12 patients (9%) with such events of grade 3 or 4, and 24 patients (18%) requiring systemic corticosteroid therapy. In 6-week landmark analysis, median PFS was 9.2 months (95% CI, 4.4 to not reached [NR]) and 4.8 months (95% CI, 3.0 to 7.5) (P = .04) whereas median OS was NR (95% CI, 12.3 to NR) and 11.1 months (95% CI, 9.6 to NR) (P = .01) for patients with or without irAEs, respectively. Multivariable analysis also revealed that irAEs were positively associated with survival outcome, with hazard ratios of 0.525 (95% CI, 0.287 to 0.937; P = .03) for PFS and 0.282 (95% CI, 0.101 to 0.667; P = .003) for OS. CONCLUSIONS AND RELEVANCE: Development of irAEs was associated with survival outcome of nivolumab treatment in patients with advanced or recurrent NSCLC. Further studies are needed to confirm our findings.
引用
- Haratani K, Hayashi H, Chiba Y, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol. 2018. PMID: 28975219. doi:10.1001/jamaoncol.2017.2925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。